CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump
Question
CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump
Direct answer
CRISPR Therapeutics reported that its commercial blood disorder treatment, Casgevy, reached $76 million in second-quarter sales, representing a 78% sequential increase relative to the prior quarter. In addition to commercial revenue acceleration, the U.S. Food and Drug Administration approved an expanded label allowing treatment of pediatric patients aged 2 and older, broadening the addressable clinical market for the gene-editing therapy. — bullish pressure on CRSP.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-09
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump”, revision 1, evidence through 2026-09-09. https://marketontology.com/catalysts/2026-09-09/crispr-therapeutics-expands-casgevy-pediatric-label-after-78-qoq-sales-jump-49d190
CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump
CRISPR Therapeutics reported that its commercial blood disorder treatment, Casgevy, reached $76 million in second-quarter sales, representing a 78% sequential increase relative to the prior quarter. In addition to commercial revenue acceleration, the U.S. Food and Drug Administration approved an expanded label allowing treatment of pediatric patients aged 2 and older, broadening the addressable clinical market for the gene-editing therapy. — bullish pressure on CRSP.
CRISPR Therapeutics reported that its commercial blood disorder treatment, Casgevy, reached $76 million in second-quarter sales, representing a 78% sequential increase relative to the prior quarter. In addition to commercial revenue acceleration, the U.S. Food and Drug Administration approved an expanded label allowing treatment of pediatric patients aged 2 and older, broadening the addressable clinical market for the gene-editing therapy.
- SummaryCRISPR Therapeutics reported that its commercial blood disorder treatment, Casgevy, reached $76 million in second-quarter sales, representing a 78% sequential increase relative to the prior quarter. In addition to commercial revenue acceleration, the U.S. Food and Drug Administration approved an expanded label allowing treatment of pediatric patients aged 2 and older, broadening the addressable clinical market for the gene-editing therapy.
- CRSPDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- CRSP closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- CRSP price vs. pre-event level
- CRSP volume vs. 20-day average
CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump
CRISPR Therapeutics reported that its commercial blood disorder treatment, Casgevy, reached $76 million in second-quarter sales, representing a 78% sequential increase relative to the prior quarter. In addition to commercial revenue acceleration, the U.S. Food and Drug Administration approved an expanded label allowing treatment of pediatric patients aged 2 and older, broadening the addressable clinical market for the gene-editing therapy. — bullish pressure on VRTX.
CRISPR Therapeutics reported that its commercial blood disorder treatment, Casgevy, reached $76 million in second-quarter sales, representing a 78% sequential increase relative to the prior quarter. In addition to commercial revenue acceleration, the U.S. Food and Drug Administration approved an expanded label allowing treatment of pediatric patients aged 2 and older, broadening the addressable clinical market for the gene-editing therapy.
- SummaryCRISPR Therapeutics reported that its commercial blood disorder treatment, Casgevy, reached $76 million in second-quarter sales, representing a 78% sequential increase relative to the prior quarter. In addition to commercial revenue acceleration, the U.S. Food and Drug Administration approved an expanded label allowing treatment of pediatric patients aged 2 and older, broadening the addressable clinical market for the gene-editing therapy.
- VRTXDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- VRTX closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- VRTX price vs. pre-event level
- VRTX volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| VRTX | Bullishdisagreed | 521.12 2026-09-09 | -1.26% | -1.51% | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
- 2026-09-24Vertex Reports Positive Phase IIb Kidney Disease Data for InaxaplinVRTX-2.99%
- 2026-09-24Vertex reports positive Phase IIb inaxaplin results for kidney diseaseVRTX-2.99%
- 2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialVRTX-2.99%
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
- 2026-09-24Vertex reports positive Phase IIb inaxaplin results for kidney diseaseVRTX-2.99%
- 2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialVRTX-2.99%
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.